Study register · detail
Harm
GRADE
Low
49 citations
Samplen = 678 Pat.
Duration3-year follow-up
ControlNon-using patients with psychotic disorder
EndpointPANSS / GAF
Blindingn.a.
DesignProspektive multizentrische Kohortenstudie (3-Jahres-Follow-up)
Key finding
Persistent cannabis use significantly worsens symptomatology, global functioning and relapse frequency in patients with non-affective psychosis.
Summary
n=678 patients with non-affective psychosis (GROUP study, Netherlands/Belgium), 3-year follow-up; persistent cannabis users had significantly more positive symptoms (PANSS positive p<0,001), more general symptoms (PANSS general p<0,001), worse global functioning (GAF symptoms p=0,017; GAF disability p<0,001) and more frequent psychosis relapses (p=0,038) compared to non-users and those who discontinued use.
P
PopulationPatients with non-affective psychotic disorder, n=678, multicentre (Netherlands/Belgium, GROUP study)
I
InterventionPersistent, newly started or discontinued cannabis use (observation of consumption pattern over 3 years)
C
ControlNon-using patients with psychotic disorder
O
OutcomePersistent cannabis users showed more positive and general symptoms, worse global functioning and more psychotic relapses vs. non-users and ex-users (PANSS positive p<0.001, PANSS general p<0.001, GAF symptoms p=0.017, GAF disability p<0.001, relapses p=0.038)
Confidence in the evidence
Low
The second of four GRADE levels, the effect estimate is of limited reliability.
Quality profile
Sample size
★★★★★
Blinding
—
Effect size
Harm
Citations / year
★★★★★
Authors
DOI
10.1017/s0033291714003092↗
Design: Prospektive multizentrische Kohortenstudie (3-Jahres-Follow-up)
Share
Abstract
Background: Prospective studies on the relationship between course of cannabis use and clinical outcome in patients with non-affective psychotic disorders are inconclusive. The current study examined whether (1) persistent, recently started, discontinued and non-cannabis-using patients with a psychotic disorder differed with regard to illness outcome at 3-year follow-up, and (2) whether timing of cannabis discontinuation was associated with course of clinical outcome. Method: This 3-year follow-up study was part of a multi-center study in the Netherlands and Belgium (Genetic Risk and Outcome of Psychosis; GROUP). We used mixed-model analyses to investigate the association between pattern of cannabis use and symptoms, global functioning and psychotic relapse. Results: In our sample of 678 patients, we found persistent users to have more positive and general symptoms, worse global functioning and more psychotic relapses compared with non-users and discontinued users [Positive and Negative Syndrome Scale (PANSS) positive, p < 0.001; PANSS general, p < 0.001; Global Assessment of Functioning (GAF) symptoms, p = 0.017; GAF disability, p < 0.001; relapses, p = 0.038]. Patients who started using cannabis after study onset were characterized by worse functioning at baseline and showed an increase in general symptoms (including depression and anxiety) at the 3-year follow-up (p = 0.005). Timing of cannabis discontinuation was not associated with clinical outcome. Conclusions: These findings suggest that cannabis use in patients with a psychotic disorder has a long-lasting negative effect on illness outcome, particularly when persistent. Treatment should focus on discouraging cannabis use.
The impediment to action advances action.